HK1028548A1 - Formulations for hydrophobic pharmaceutical agents - Google Patents
Formulations for hydrophobic pharmaceutical agentsInfo
- Publication number
- HK1028548A1 HK1028548A1 HK00106875.7A HK00106875A HK1028548A1 HK 1028548 A1 HK1028548 A1 HK 1028548A1 HK 00106875 A HK00106875 A HK 00106875A HK 1028548 A1 HK1028548 A1 HK 1028548A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- formulations
- pharmaceutical agents
- hydrophobic pharmaceutical
- solid
- hydrophobic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3987097P | 1997-03-05 | 1997-03-05 | |
US4125197P | 1997-03-18 | 1997-03-18 | |
PCT/US1998/004134 WO1998038984A2 (en) | 1997-03-05 | 1998-03-04 | Formulations for hydrophobic pharmaceutical agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1028548A1 true HK1028548A1 (en) | 2001-02-23 |
Family
ID=26716539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00106875.7A HK1028548A1 (en) | 1997-03-05 | 2000-10-28 | Formulations for hydrophobic pharmaceutical agents |
Country Status (11)
Country | Link |
---|---|
US (2) | US6248771B1 (de) |
EP (1) | EP1014953B1 (de) |
JP (1) | JP4713698B2 (de) |
AT (1) | ATE554750T1 (de) |
AU (1) | AU743024B2 (de) |
CA (1) | CA2282439C (de) |
CO (1) | CO4940469A1 (de) |
ES (1) | ES2384551T3 (de) |
HK (1) | HK1028548A1 (de) |
NZ (1) | NZ510991A (de) |
WO (1) | WO1998038984A2 (de) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846839B1 (en) | 1995-06-07 | 2005-01-25 | Sugen, Inc. | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6235769B1 (en) | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
ES2429573T3 (es) | 1998-05-29 | 2013-11-15 | Sugen, Inc. | Derivado de 2-indolinona sustituido por un pirrol como inhibidor de proteína kinasa |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP1162974A1 (de) * | 1999-03-19 | 2001-12-19 | Parker Hughes Institute | Quinazoline formulierungen und therapeutische verwendung |
US7064114B2 (en) | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
PT1169054E (pt) * | 1999-04-09 | 2004-11-30 | Max Planck Gesellschaft | Produtos e metodos para tratar doencas relacionadas com ptp lar |
ATE375984T1 (de) | 1999-07-07 | 2007-11-15 | Astrazeneca Uk Ltd | Chinazolin derivate |
GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
US6878733B1 (en) | 1999-11-24 | 2005-04-12 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
EP1259234B9 (de) * | 1999-12-30 | 2007-02-14 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie |
EP1272185B1 (de) | 2000-03-06 | 2005-07-27 | AstraZeneca AB | Verwendung von quinazolinderivate als inhibitoren der angiogenese |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
CA2410509A1 (en) | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
DE60136459D1 (de) | 2000-06-24 | 2008-12-18 | Astrazeneca Ab | Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten |
AU2002216758A1 (en) * | 2000-07-03 | 2002-01-14 | Astrazeneca Ab | Quinazolines with therapeutic use |
ATE290372T1 (de) * | 2000-07-24 | 2005-03-15 | Upjohn Co | Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln |
CN1469707A (zh) * | 2000-08-10 | 2004-01-21 | �¶���˹ҩƷ��˾ | 改进的疏水性药物的固体药物剂量制剂 |
US20050158271A1 (en) * | 2000-10-11 | 2005-07-21 | Lee Sang C. | Pharmaceutical applications of hydrotropic polymer micelles |
WO2002030466A2 (en) * | 2000-10-11 | 2002-04-18 | Purdue Research Foundation | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof |
WO2002069936A2 (en) * | 2001-03-02 | 2002-09-12 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical composition of ibuprofen |
US6912582B2 (en) | 2001-03-30 | 2005-06-28 | Microsoft Corporation | Service routing and web integration in a distributed multi-site user authentication system |
WO2002096361A2 (en) | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
US6720002B2 (en) * | 2001-07-20 | 2004-04-13 | R.P. Scherer Technologies, Inc. | Antihistamine formulations for soft capsule dosage forms |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
AU2002346457A1 (en) * | 2001-11-21 | 2003-06-10 | Pharmacia And Upjohn Company | Pharmaceutical formulations comprising indolinone derivatives |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
EP1471910A2 (de) * | 2002-01-17 | 2004-11-03 | Neurogen Corporation | Substituirte chinazolin-4-ylamine analogue als capsaicinreceptoren-modulatoren |
AU2003216282A1 (en) * | 2002-02-15 | 2003-09-09 | Pharmacia And Upjohn Company Llc | Process for preparing indolinone derivatives |
BRPI0307786B8 (pt) * | 2002-02-26 | 2021-05-25 | Astrazeneca Ab | composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água |
DE60329910D1 (de) * | 2002-03-29 | 2009-12-17 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
JP4513566B2 (ja) | 2002-04-26 | 2010-07-28 | 日本新薬株式会社 | キナゾリン誘導体及び医薬 |
EP1569926A1 (de) * | 2002-12-13 | 2005-09-07 | Neurogen Corporation | Carbonsäure-, phosphat- oder phosphonatsubstituierte chinazolin-4-ylaminanaloga als capsaicinrezeptormodulatoren |
ITRM20030074A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Formulazioni semisolide a rilascio immediato intese |
US7893096B2 (en) * | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
CN1774250A (zh) | 2003-04-16 | 2006-05-17 | 霍夫曼-拉罗奇有限公司 | 作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6-(苯氧基)-吡啶并[3,4-d]嘧啶-2-基)-胺衍生物 |
MXPA05011103A (es) | 2003-04-16 | 2005-12-12 | Hoffmann La Roche | Compuestos de quinazolina. |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
US7329664B2 (en) * | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
SI1667991T1 (sl) | 2003-09-16 | 2008-10-31 | Astrazeneca Ab | Kinazolinski derivati kot inhibitorji tirozin kinaze |
WO2005037273A1 (en) * | 2003-10-16 | 2005-04-28 | Chiron Corporation | Substituted benzazoles and use thereof as inhibitors of raf kinase |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
UA85706C2 (en) | 2004-05-06 | 2009-02-25 | Уорнер-Ламберт Компани Ллси | 4-phenylaminoquinazolin-6-yl amides |
US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
JP5001150B2 (ja) * | 2004-06-08 | 2012-08-15 | ファミリーズ オブ スパイナル マスキュラー アトロフィー | 脊髄性筋萎縮症のための2,4−ジアミノキナゾリン |
MX2007005408A (es) * | 2004-11-09 | 2007-05-16 | Hoffmann La Roche | Compuestos de aminoquinazolinas. |
ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
PL1885342T3 (pl) * | 2005-03-21 | 2016-10-31 | Inhibitor krystalizacji i jego zastosowanie w kapsułkach żelatynowych | |
DE602006018331D1 (de) | 2005-09-20 | 2010-12-30 | Astrazeneca Ab | 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs |
JP5167144B2 (ja) * | 2005-12-22 | 2013-03-21 | アストラゼネカ アクチボラグ | 併用療法 |
US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
CA2643044A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
AU2007281217B2 (en) | 2006-08-01 | 2013-09-12 | Families Of Spinal Muscular Atrophy | 2,4-Diaminoquinazolines for spinal muscular atrophy |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
EP2118075A1 (de) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2009042114A2 (en) | 2007-09-21 | 2009-04-02 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
JP5336516B2 (ja) | 2008-02-07 | 2013-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法 |
WO2009114365A2 (en) * | 2008-03-13 | 2009-09-17 | Mallinckrodt Inc. | Multi-function, foot-activated controller for imaging system |
ES2444128T3 (es) | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | Nueva SAL-554 |
US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
JP5359333B2 (ja) * | 2009-02-05 | 2013-12-04 | ゼリア新薬工業株式会社 | コロソリン酸含有水性液剤 |
KR20110124787A (ko) * | 2009-02-27 | 2011-11-17 | 암비트 바이오사이언시즈 코포레이션 | Jak 키나아제 조절 퀴나졸린 유도체 및 이의 사용 방법 |
EP3575288B1 (de) | 2009-09-03 | 2021-10-27 | Bristol-Myers Squibb Company | Chinazoline als kaliumionenkanalhemmer |
US9023886B2 (en) * | 2009-11-10 | 2015-05-05 | Celgene Corporation | Nanosuspension of a poorly soluble drug via microfluidization process |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
CN102716103B (zh) * | 2012-07-02 | 2013-12-18 | 西安力邦制药有限公司 | 2,2′,6,6′-四异丙基-4,4′-二联苯酚软胶囊制剂及其制备方法 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
CN103837615B (zh) * | 2014-02-15 | 2015-05-20 | 青岛农业大学 | 一种应用高效液相色谱法同时测定植物蜕皮激素类物质的方法 |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1030687A (en) | 1972-09-26 | 1978-05-02 | Hideyoshi Tugukuni | Powdery coating composition and process for preparing the same |
US3850939A (en) | 1973-02-20 | 1974-11-26 | Parke Davis & Co | 5-nitro-2-thiazolylthiopyridine,1-oxides |
US4992271A (en) | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
JPS59190967A (ja) * | 1983-04-15 | 1984-10-29 | Hokuriku Seiyaku Co Ltd | 1−(2,6−ジフルオロフエニル)−2−インドリノン誘導体 |
JPS61167616A (ja) * | 1985-01-22 | 1986-07-29 | Adeka Argus Chem Co Ltd | 放射線増感剤 |
EP0448841B1 (de) | 1990-03-19 | 1993-06-02 | Agfa-Gevaert N.V. | Elektronenacceptoren enthaltende Photomaterialien |
DE69118388T2 (de) | 1990-09-10 | 1996-11-14 | Rhone Poulenc Rorer Int | Substituierte bizyklische arylderivate mit selektiver leukotrien b4 antagonistischer wirkung |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5610173A (en) | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9501567D0 (en) * | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US5763470A (en) * | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
WO1996040113A2 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Phosphatase inhibitors |
EP0832073B1 (de) * | 1995-06-07 | 2002-01-16 | Sugen, Inc. | Chinazoline und pharmazeutische zusammensetzungen |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
-
1998
- 1998-03-04 CO CO98011791A patent/CO4940469A1/es unknown
- 1998-03-04 AT AT98908884T patent/ATE554750T1/de active
- 1998-03-04 AU AU66806/98A patent/AU743024B2/en not_active Ceased
- 1998-03-04 EP EP98908884A patent/EP1014953B1/de not_active Expired - Lifetime
- 1998-03-04 NZ NZ510991A patent/NZ510991A/xx not_active IP Right Cessation
- 1998-03-04 CA CA2282439A patent/CA2282439C/en not_active Expired - Fee Related
- 1998-03-04 ES ES98908884T patent/ES2384551T3/es not_active Expired - Lifetime
- 1998-03-04 US US09/034,374 patent/US6248771B1/en not_active Expired - Lifetime
- 1998-03-04 JP JP53869898A patent/JP4713698B2/ja not_active Expired - Fee Related
- 1998-03-04 WO PCT/US1998/004134 patent/WO1998038984A2/en active IP Right Grant
-
2000
- 2000-10-28 HK HK00106875.7A patent/HK1028548A1/xx not_active IP Right Cessation
-
2001
- 2001-03-05 US US09/797,842 patent/US6696482B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1014953B1 (de) | 2012-04-25 |
AU743024B2 (en) | 2002-01-17 |
US6696482B2 (en) | 2004-02-24 |
JP2001514626A (ja) | 2001-09-11 |
ES2384551T3 (es) | 2012-07-06 |
US20010012844A1 (en) | 2001-08-09 |
EP1014953A2 (de) | 2000-07-05 |
CA2282439C (en) | 2010-05-04 |
JP4713698B2 (ja) | 2011-06-29 |
US6248771B1 (en) | 2001-06-19 |
CA2282439A1 (en) | 1998-09-11 |
CO4940469A1 (es) | 2000-07-24 |
WO1998038984A3 (en) | 1999-01-28 |
NZ510991A (en) | 2002-11-26 |
AU6680698A (en) | 1998-09-22 |
ATE554750T1 (de) | 2012-05-15 |
WO1998038984A2 (en) | 1998-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1028548A1 (en) | Formulations for hydrophobic pharmaceutical agents | |
BR9902086A (pt) | Formulações farmacêuticas. | |
PT960107E (pt) | Compostos de paclitaxel 6-tio-substituidos | |
AP1697A (en) | Azabicycloalkanes as CCR5 modulators. | |
PL337499A1 (en) | Novel 2-(iminomethyl)aminophenylic derivatives, their production and application as drugs and pharmaceutic agents containing such derivatives | |
ZA985364B (en) | Pharmaceutical formulations containing voriconazole. | |
SE9702001D0 (sv) | Novel compounds | |
NZ527157A (en) | Compositions for delivering bisphosphonates | |
IL133397A0 (en) | Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin | |
IL128425A0 (en) | Taxane derivatives their preparation and pharmaceutical compositions containing them | |
ZA979550B (en) | Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them. | |
HRP20020330B1 (de) | ||
PL343156A1 (en) | Method for stabilizing pharmaceutical compositions by special use of an antioxidant | |
AU2001289438A1 (en) | Pharmaceutical semi-solid composition of isotretinoin | |
CY2261B1 (en) | Cytotoxic amino sugar and relatd sugar derivativesof indolopyrrolocarbazoles | |
IL140140A0 (en) | Thyroid hormone analogues and methods for their preparation | |
ZA9811833B (en) | Pharmaceutical compositions of uridine triphosphate. | |
GEP20094818B (en) | 2-methyl-thieno-benzodiaze-pine formulation | |
ATE240303T1 (de) | 1,2,4-triazol-3-thion verbindungen | |
MY126868A (en) | Suspension comprising oxcarbazepine | |
MY127474A (en) | Naphthyl compounds, intermediates, compositions, and methods of use | |
AP2001002369A0 (en) | Pharmaceutical complex. | |
PL340459A1 (en) | Agonists of 5ht1f | |
NZ223521A (en) | Substituted n-phenyl benzamide derivatives and anticonvulsive pharmaceutical compositions | |
WO1998030190A3 (en) | Colon cancer KH-1 and N3 antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160304 |